Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts
- 1 December 2010
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 22 (5), 1113-1119
- https://doi.org/10.1093/annonc/mdq570
Abstract
Background: Metastatic breast cancer (MBC) is currently an incurable condition that is primarily treated with palliative measures. Isolation of circulating tumor cells (CTCs) from the peripheral blood of these patients provides a predictive prognostic indicator, independent of the type of therapy, site of occurrence and biological characteristics of the primary disease. It has been well established that glycosylation processing pathways are disturbed in cancer, leading to alterations in the glycan content of glycoproteins. Materials and methods: The bi-, tri- and tetraantennary glycans containing sialyl Lewis x (sLex) epitopes (A2F1G1, A3F1G1, A4F1G1 and A4F2G2) were quantified using normal phase high-performance liquid chromatography in combination with exoglycosidase array digestions in the glycan pools released from sera of 27 patients with advanced breast cancer (16 with CTCs Results: The levels of all these glycans were significantly higher in patients with CTCs ≥5/7.5 ml compared with patients with CTCs Conclusions: As high levels of glycans containing sLex epitopes were associated with CTCs, their measurement may provide a new noninvasive approach for determining prognosis in women with MBC.Keywords
This publication has 34 references indexed in Scilit:
- Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patientsGlycobiology, 2010
- Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery EquationClinical Chemistry, 2010
- Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor CellsJNCI Journal of the National Cancer Institute, 2009
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expressionBMC Cancer, 2007
- Cancer-Associated Glycoforms of Gelatinase B Exhibit a Decreased Level of Binding to Galectin-3Biochemistry, 2006
- Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer PatientsJournal of Clinical Oncology, 2006
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinomaOncogene, 2002